OraLiva

OraLiva, Inc. specializes in developing noninvasive, AI-linked diagnostic solutions for the early detection of oral cancer and oral dysplasia. The company operates in the healthcare diagnostics market, targeting both research institutions and clinical settings. OraLiva's core product is a next-generation programmable single cell cytology platform, which is designed to provide reliable and painless diagnostics. This platform is clinically validated and allows for rapid expansion to a broad range of tests, making it versatile for various types of cancer detection. The business model is centered around providing point-of-care testing solutions, which are near-patient testing technologies that offer quick and accurate results. OraLiva generates revenue through the sale of its diagnostic devices and associated testing services. The company collaborates with prominent research institutions, such as the McDevitt Laboratory at NYU, to conduct large clinical studies and validate its technology. OraLiva's first application is set to launch in 2024, focusing on oral cancer detection, which is one of the most expensive and challenging cancers to treat. By enabling early detection, OraLiva aims to save lives and reduce healthcare costs.

Keywords: AI-linked diagnostics, oral cancer, noninvasive, single cell cytology, early detection, point-of-care, clinically validated, healthcare diagnostics, programmable platform, research collaboration.